Amvuttra (vutrisiran)
OrphanAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- vutrisiran
- Company
- Alnylam Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Amyloid Neuropathies, Familial
- CHMP opinion
- Thu 21 Jul 2022
- EU approval
- Thu 15 Sep 2022
- Designations
- Orphan, Additional monitoring
- Application
- EMEA/H/C/005852
- ATC
- N07XX18
- Official record
- www.ema.europa.eu
Indication
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Regulatory milestones
No milestones recorded in the last year.
Follow Amvuttra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.